Allianz Asset Management
EVFM

Allianz Asset Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Allianz Asset Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-767
Closed -$61K – 2599
2020
Q1 		$61K Sell
767
-1
-0.1% -$80 ﹤0.01% 2418
2019
Q4 		$71K Buy
+768
New +$64.8K ﹤0.01% 2730

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Allianz Asset Management's EVFM Position: Q2 2020 in Review

Allianz Asset Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2020, closing a stake of 767 shares — an estimated $61K sold.

Allianz Asset Management first reported a position in EVFM in Q4 2019 and held it in 2 quarters. The position peaked at $71K in Q4 2019. 122 funds tracked by Wall St. Rank hold EVFM as of Q2 2020.

  • Allianz Asset Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Allianz Asset Management sold 767 Evofem Biosciences, Inc. Common Stock shares in Q2 2020, an estimated $61K.
  • Allianz Asset Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Allianz Asset Management's Evofem Biosciences, Inc. Common Stock position peaked at $71K in Q4 2019.
  • 122 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2020.

Based on Allianz Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.